Conflict of Interest

In the May 2018 issue of Current Psychiatry, there’s an editorial by Henry Nasrallah, MD. Dr. Nasrallah is a highly renowned psychiatrist, and is Editor-in-Chief of the journal. He is also chair of the St. Louis University Department of Psychiatry. Here’s the opening paragraph of the article. "As the end of the academic year approaches, I always think of one last message to send to the freshly minted psychiatrists who will complete their 4 years of post-MD training. This year, I thought of emphasizing the principles of psychiatric practice, which the graduates will deliver for the next 4 to 5 decades of their professional lives. Those essential principles are coded in the DNA of psychiatric practice, just as the construction of all organs in the human body is coded within the DNA of the 22,000 genes that comprise our 23 chromosomes." ...

INTRODUCTION On May 5, 2017, Donald Goff, MD and seven other psychiatrists, including the very eminent Jeffrey Lieberman, MD, published an article in the American Journal of Psychiatry. The title is: The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. Here’s the abstract: "Concerns have been raised that treatment with antipsychotic medication might adversely affect long-term outcomes for people with schizophrenia. The evidence cited for these concerns includes the association of antipsychotic treatment with brain volume reduction and with dopamine receptor sensitization, which might make patients vulnerable to relapse and illness progression. An international group of experts was convened to examine findings from clinical and basic research relevant to these concerns. Little evidence was found to support a negative long-term effect of initial or maintenance antipsychotic treatment on outcomes, compared with withholding treatment. Randomized controlled trials strongly support the efficacy of antipsychotics for the acute treatment of psychosis and prevention of relapse; correlational evidence suggests that early intervention and reduced duration of untreated psychosis might improve longer-term outcomes. Strategies for treatment discontinuation or alternative nonpharmacologic treatment approaches may benefit a subgroup of patients but may be associated with incremental risk of relapse and require further study, including the development of biomarkers that will enable a precision medicine approach to individualized treatment." ...

On December 25, 2016, the Baltimore Sun published an excellent article titled Drug companies prey on children, by Patrick D. Hahn, PhD. Dr. Hahn is an affiliate professor of biology at Loyola University, Maryland. Here are some quotes: "I recently attended Youth Mental Health First Aid Training at a local public school. It was an eye-opening experience." "Youth Mental Health First Aid Training, sponsored by the National Council for Behavioral Health, is intended to enable teachers, parents and others in contact with young people to identify potential 'mental illnesses' in order to facilitate early detection and treatment by our mental health care system. My fellow attendees were surprisingly open about their own experiences with that system. One mentioned that her son became manic after being diagnosed for ADHD. Another said that both she and her roommate became bipolar after being diagnosed for depression. Neither our facilitators nor anyone else present pointed out that mania and bipolar disorder are toxic effects of medications commonly prescribed for ADHD and depression." ...

On July 6, HB 2646 (the Tim Murphy Bill) passed the US House and was sent to the Senate. At the present time, a related bill is working its way through the Senate. This is SB 2680, The Mental Health Reform Act 2016. It is sponsored by Lamar Alexander (R-TN), Patty Murray (D-WA), Bill Cassidy (R-LA), Chris Murphy (D-CT), David Vitter (R-LA), and Al Franken (D-MN). The wording of the bill was finalized in March of this year, and it passed out of committee on March 16. ...

In the October 2015 issue of the Behavior Therapist (pages 206-213), Jeffrey Lacasse, PhD, and Jonathan Leo, PhD, published an article titled Antidepressants and the Chemical Imbalance Theory of Depression: A Reflection and Update on the Discourse, I thought the article had particular merit, and I drew attention to it in a post dated November 2. The post, More on the Chemical Imbalance Theory, was also published on Mad in America. In that post, I quoted a number of passages from the Behavior Therapist article, including: ...

BACKGROUND On June 19, 2015, I published a post titled Allen Frances’ Ties to Johnson & Johnson. In that post, I set out some very serious allegations against Dr. Frances. I drew these allegations from a document titled Special Witness Report dated October 15, 2010. The report was written by David Rothman, PhD, Professor of Social Medicine at Columbia College of Physicians and Surgeons. Dr. Rothman’s report was produced in the context of a lawsuit filed by the State of Texas against Janssen Pharmaceutica, a subsidiary of Johnson & Johnson. ...

INTRODUCTION I recently came across an article titled Diagnosisgate: Conflict of Interest at the Top of the Psychiatric Apparatus, by Paula Caplan, PhD. The article was published in Aporia, the University of Ottawa nursing journal, in January 2015. Aporia is “a peer-reviewed, bilingual, and open access journal dedicated to scholarly debates in nursing and the health sciences.” Dr, Caplan is a clinical and research psychologist, and an Associate at Harvard’s DuBois Institute. She worked as a consultant to the DSM-IV task force in the 1980’s, but resigned from this position after two years. Here’s a quote from her February 2014 post on Mad in America The Great “Crazy” Cover-up: Harm Results from Rewriting the History of DSM: ...

In November of last year, the Schizophrenia Bulletin published online a research study: Antipsychotic Treatment and Mortality in Schizophrenia, by Minna Torniainen et al. The research was conducted in Sweden. The authors offer the following background for the study: "It is generally believed that long-term use of antipsychotics increases mortality and, especially, the risk of cardiovascular death. However, there are no solid data to substantiate this view." and the following conclusions: "Among patients with schizophrenia, the cumulative antipsychotic exposure displays a U-shaped curve for overall mortality, revealing the highest risk of death among those patients with no antipsychotic use. These results indicate that both excess overall and cardiovascular mortality in schizophrenia is attributable to other factors than antipsychotic treatment when used in adequate dosages." ...

In 2010, Acta Psychiatrica Scandinavica published a study by Göran Isacsson et al. The paper was titled Antidepressant medication prevents suicide in depression. Here's the conclusion: "The finding that in-patient care for depression did not increase the probability of the detection of antidepressants in suicides is difficult to explain other than by the assumption that a substantial number of depressed individuals were saved from suicide by postdischarge treatment with antidepressant medication." ...

On August 20, 2014, Psychiatry Advisor published an article on its website. The article was written by Leslie Citrome, MD, a professor of psychiatry at New York Medical College in Valhalla, NY, and a member of the Board of Directors of the American Society of Clinical Psychopharmacology. The article is called Is Bias Against Pharma-Funded Research Fair? This is an interesting title, because bias, by its very definition, is unfair. So the very wording of the question begs the question – which strikes me as unfair. But let’s put that aside. ...